Pattern Computer Advances Promising Combination Therapy Candidates for Triple-Negative Breast Cancer Through Round Two of Targeted In Vivo Studies
REDMOND, WA, APRIL 14, 2022 — Pattern Computer®, Inc. (PCI) is pleased to announce the advancement of our potential combination therapy candidates against Triple-negative breast cancer (TNBC) to pre-clinical validation through focused animal studies. Data from previous studies at a leading global clinical research organization support the validity and promise of our combinations as treatment options for TNBC.
We are announcing today that one of the candidate inhibitor combinations, which displayed good synergistic antiproliferative response in two human TNBC cell lines-derived xenograft models, was well-tolerated even at high doses. Based on this encouraging data, we are taking the next logical step for a follow-on animal study to evaluate the antiproliferative effect in a cell line that might be particularly susceptible to our candidate therapy. The outcome of this study should support and inform the selection of the right patient population for subsequent human clinical trials.
PCI’s drug discovery efforts are currently focused on oncological malignancies. Using our innovative Pattern Discovery Engine™ (PDE), we have identified and have under preclinical development, two sets of potential combination therapies for TNBC, the most difficult to treat and most aggressive subtype of breast cancer. Our capability for discovering polythetic patterns of interacting genes in genomics data is only made possible by the PDE. In addition, we are actively and aggressively applying this to other complex and intractable cancers including High-grade Serous Ovarian Cancer, and metastatic Castration-Resistant Prostate Cancer (mCRPC).
“We are excited to be able to bring this drug candidate into the next round of testing, targeting the triple negative subclass of breast cancer, the only subclass without a direct treatment today. Once completed successfully, we look forward to seeing it move rapidly into human clinical trials, and into the real task of saving lives. We have chosen this particular path, in part, for its relatively short FDA approval runway.
“And, as part of our larger StarBright Project, this announcement represents both one of two different candidates under test for this disease, and additional successful work to date in addressing all of the top five cancer killers.
“By making a positive difference in TPN Breast Cancer, Ovarian Cancer, Lung Cancer, Colorectal Cancer, and Metastatic Prostate Cancer, we hope to show that this new Pattern Discovery Engine approach to medicine will indeed be disruptive, both in making major steps forward in oncology and other fields, and in moving far beyond the results of yesterday’s mathematical tools,” Pattern Computer CEO Mark Anderson added.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional COVID detection, biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
CONTACT: Brad Holtz – 301.529.9944 – bh@patterncomputer.com
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
Copyright ยฉ 2022 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, Dimensional Navigator, and ProSpectral are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.